<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>j.jaad.2018.10.079</title><style type="text/css"> * {margin:0; padding:0; text-indent:0; }
 .s1 { color: black; font-family:"Palatino Linotype", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 16pt; }
 .s2 { color: black; font-family:"Palatino Linotype", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 11pt; }
 .s3 { color: black; font-family:"Palatino Linotype", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 18pt; }
 .s4 { color: black; font-family:"Times New Roman", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 18pt; }
 .p, p { color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; margin:0pt; }
 .s5 { color: #007FAC; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s6 { color: black; font-family:"Times New Roman", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s7 { color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; }
 .s8 { color: black; font-family:"Palatino Linotype", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s9 { color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s10 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6pt; }
 .s11 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9.5pt; }
 .s12 { color: black; font-family:"Bookman Old Style", serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 9.5pt; }
 .s13 { color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 48pt; }
 .s14 { color: #007FAC; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s15 { color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 1pt; }
 .s16 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .a, a { color: #007FAC; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s17 { color: black; font-family:"Arial Black", sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s18 { color: #007FAC; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s19 { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s20 { color: black; font-family:Calibri, sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s21 { color: black; font-family:"Palatino Linotype", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s22 { color: black; font-family:Cambria, serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s23 { color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s24 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s25 { color: black; font-family:"Palatino Linotype", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 7pt; }
 .s26 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s27 { color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 5pt; vertical-align: 1pt; }
 .s28 { color: black; font-family:Calibri, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s30 { color: #007FAC; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 6.5pt; }
 .s31 { color: black; font-family:"Palatino Linotype", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt; }
 .s32 { color: black; font-family:Cambria, serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 10pt; }
 .s34 { color: black; font-family:"Palatino Linotype", serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s35 { color: #007FAC; font-family:Calibri, sans-serif; font-style: italic; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s36 { color: #007FAC; font-family:宋体; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 .s38 { color: #007FAC; font-family:宋体; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 li {display: block; }
 #l1 {padding-left: 0pt;counter-reset: c1 1; }
 #l1> li>*:first-child:before {counter-increment: c1; content: counter(c1, decimal)". "; color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt; }
 #l1> li:first-child>*:first-child:before {counter-increment: c1 0;  }
</style></head><body><p class="s1" style="padding-left: 21pt;text-indent: 0pt;line-height: 21pt;text-align: center;"><a name="bookmark0">C</a><span class="s2">ONTINUING  MEDICAL EDUCATION</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><span><img width="619" height="19" alt="image" src="Image_001.png"/></span></p><p class="s3" style="padding-top: 6pt;padding-left: 150pt;text-indent: -80pt;line-height: 70%;text-align: left;">Basic  chemical  peeling:  Superficial  and       <span><img width="32" height="32" alt="image" src="Image_002.png"/></span><span class="s4"> </span>medium-depth peels</p><p class="s14" style="padding-top: 14pt;padding-left: 21pt;text-indent: 0pt;text-align: center;"><a href="#bookmark32" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Kachiu C. Lee, MD, MPH,</a><a href="#bookmark32" class="s5">a</a> <a href="#bookmark33" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Carlos G. Wambier, MD, PhD,</a><a href="#bookmark33" class="s5">b</a> <a href="#bookmark34" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Seaver L. Soon, MD,</a><a href="#bookmark34" class="s5">c</a></p><p class="s14" style="padding-left: 176pt;text-indent: -170pt;line-height: 106%;text-align: left;"><a href="#bookmark35" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">J. Barton Sterling, MD,</a><a href="#bookmark35" class="s5">d</a> <a href="#bookmark36" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Marina Landau, MD,</a><a href="#bookmark36" class="s5">e</a> <a href="#bookmark37" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Peter Rullan, MD,</a><a href="#bookmark37" class="s5">f</a> <a href="#bookmark38" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">and Harold J. Brody, MD,</a><a href="#bookmark38" class="s5">g</a> <span style=" color: #000;">on behalf of the International Peeling Society</span></p><p class="s6" style="padding-left: 21pt;text-indent: 0pt;line-height: 11pt;text-align: center;">Providence, Rhode Island; New Haven, Connecticut; San Diego, California; Spring Lake, New Jersey;</p><p class="s6" style="padding-left: 21pt;text-indent: 0pt;text-align: center;">Holon, Israel; and Atlanta,  Georgia</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s7" style="padding-bottom: 2pt;padding-left: 23pt;text-indent: 0pt;text-align: justify;">Chemical peeling, or chemexfoliation, has been used for centuries to improve signs of ultraviolet</p><p class="s8" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Learning objectives</p><p class="s9" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 113%;text-align: justify;">After completing this learning activity, participants should be able to discuss the components (pH, composition, vehicle) affecting tolerability and safety of superficial and medium- depth peels; explain the differences between the three major medium depth peels: JS<span class="s10">1</span>TCA, CO2<span class="s10">1</span>TCA, glycolic acid<span class="s10">1</span>TCA; and recognize the level of injury of superficial vs medium depth peels.</p><p class="s8" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Disclosures Editors</p><p class="s9" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 118%;text-align: justify;">The editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s).</p><p class="s8" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Authors</p><p class="s9" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">The authors involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).</p><p class="s8" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Planners</p><p class="s9" style="padding-left: 5pt;text-indent: 0pt;line-height: 118%;text-align: justify;">The planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"/><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s7" style="padding-left: 23pt;text-indent: 0pt;line-height: 107%;text-align: justify;">light<span class="s11">e</span>induced sun damage. Over the last 30 years, the science behind chemical peeling has evolved, increasing our understanding of the role of peeling ingredients and treatment indications. The depth of peels is directly related to improved results and to the number of complications that can occur. Key principles for superficial and medium depth peeling are discussed, as well as appropriate indications for these treatments. ( J Am Acad Dermatol 2019;81:313-24.)</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s12" style="padding-left: 23pt;text-indent: 0pt;line-height: 107%;text-align: left;">Key words: <span class="s7">acne; chemabrasion; chemexfoliation; chemical peeling; glycolic acid; International Peeling Society; Jessner’s solution; pyruvic acid; rejuvenation; retinoic acid; salicylic acid; solid CO2; trichloroacetic acid.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s13" style="text-indent: 0pt;line-height: 48pt;text-align: left;">C</p><p style="text-indent: 0pt;text-align: left;"/><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 34pt;line-height: 106%;text-align: right;">hemical peeling is the controlled wounding of the epidermis and dermis for medical and aesthetic improvement. Although the use of chemical peels dates to ancient Egyptian times, our</p><p class="s14" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark50" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">understanding of the science behind chemical peeling is still evolving.</a>1 <span style=" color: #000;">Recent scientific studies investigating the histologic and long-term effects of peels provide data to support the clinical</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s15" style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="299" height="0" alt="image" src="Image_003.png"/></span>	<span><img width="292" height="0" alt="image" src="Image_004.png"/></span></p><p class="s16" style="padding-top: 4pt;padding-left: 15pt;text-indent: -10pt;line-height: 108%;text-align: justify;"><a name="bookmark32">From the Department of Dermatology,a Warren Alpert School of Medicine, Brown University, Providence; Department of Dermatology,b Yale University School of Medicine, New Haven; Division of Dermatology,c Scripps Clinic, and the Department of Dermatology,f University of California San Diego, San Diego; Jersey Shore University Medical Center,d Spring Lake; Dermatology Unit,e Wolfson Medical Center, Holon; and the Department of Dermatology,g Emory University School of Medicine, Atlanta.</a><a name="bookmark33">&zwnj;</a><a name="bookmark34">&zwnj;</a><a name="bookmark35">&zwnj;</a><a name="bookmark36">&zwnj;</a><a name="bookmark37">&zwnj;</a><a name="bookmark38">&zwnj;</a></p><p class="s16" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Funding sources: None.</p><p class="s16" style="padding-left: 5pt;text-indent: 0pt;line-height: 108%;text-align: justify;">Conflicts of interest: None declared. Accepted for publication October 3, 2018.</p><p class="s18" style="padding-left: 15pt;text-indent: -10pt;line-height: 108%;text-align: left;"><a href="mailto:kachiu@gmail.com" style=" color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt;" target="_blank">Reprint requests: Kachiu C. Lee, MD, MPH, 593 Eddy St, APC 10, Providence, RI 02903. E-mail: </a>kachiu@gmail.com<span style=" color: #000;">.</span></p><p class="s16" style="padding-left: 5pt;text-indent: 0pt;line-height: 9pt;text-align: left;">0190-9622/$36.00</p><p class="s17" style="padding-left: 15pt;text-indent: -10pt;text-align: left;">© <span class="s16">2018 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.</span></p><p class="s18" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">https://doi.org/10.1016/j.jaad.2018.10.079 <span class="s19">Date of release: August 2019 Expiration date: August 2022</span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="76" height="58" alt="Unlabelled image" title="Unlabelled image" src="Image_005.gif"/></span></p><p class="s16" style="padding-top: 3pt;padding-left: 76pt;text-indent: 0pt;line-height: 107%;text-align: justify;">Scanning this QR code will direct you to the CME quiz in the American Academy of Der- matology’s (AAD) online learning center where after taking the quiz and successfully passing it, you may claim <span class="s20">1 AMA PRA Category 1 credit</span><a href="http://www.aad.org/" style=" color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt;" target="_blank">. NOTE: You must have an AAD account and be signed in on your device in order to be directed to the CME quiz. If you do not have an AAD account, you will need to create one. To create an AAD  account:  go to the  AAD’s website: </a><span style=" color: #007FAC;">www.aad.org</span>.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="text-indent: 0pt;text-align: right;">313</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s22" style="padding-top: 5pt;padding-left: 12pt;text-indent: 0pt;text-align: left;">Abbreviations used:</p><p class="s23" style="padding-top: 6pt;padding-left: 12pt;text-indent: 0pt;line-height: 88%;text-align: left;">CO2:    solid carbon dioxide or dry ice CROSS: chemical reconstruction of skin scars GA: glycolic acid</p><p class="s23" style="padding-left: 12pt;text-indent: 0pt;line-height: 9pt;text-align: left;">HA: hydroalcoholic</p><p class="s23" style="padding-left: 12pt;text-indent: 0pt;line-height: 9pt;text-align: left;">JS: Jessner solution</p><p class="s23" style="padding-left: 12pt;text-indent: 0pt;line-height: 9pt;text-align: left;">LA: lactic acid</p><p class="s23" style="padding-left: 12pt;text-indent: 0pt;line-height: 89%;text-align: left;">MJS:  modified Jessner solution PA: pyruvic acid</p><p class="s23" style="padding-left: 12pt;text-indent: 0pt;line-height: 9pt;text-align: left;">PEG: polyethylene glycol</p><p class="s23" style="padding-left: 12pt;text-indent: 0pt;line-height: 88%;text-align: left;">PIH:  postinflammatory hyperpigmentation SA: salicylic acid</p><p class="s23" style="padding-left: 12pt;text-indent: 0pt;line-height: 9pt;text-align: left;">TCA: trichloroacetic acid</p><p style="text-indent: 0pt;text-align: left;"/><p class="s21" style="padding-top: 2pt;padding-bottom: 4pt;padding-left: 250pt;text-indent: 0pt;text-align: left;"><a name="bookmark1">Table I. </a><span class="s24">Depth of penetration of trichloroacetic acid chemical peels</span><a name="bookmark2">&zwnj;</a><a name="bookmark3">&zwnj;</a><a name="bookmark4">&zwnj;</a><a name="bookmark39">&zwnj;</a></p><p style="padding-left: 250pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="295" height="1" alt="image" src="Image_006.png"/></span></p><p class="s25" style="padding-top: 2pt;padding-left: 250pt;text-indent: 0pt;line-height: 9pt;text-align: left;">Peel strength</p><p class="s25" style="padding-left: 250pt;text-indent: 0pt;line-height: 9pt;text-align: left;">of TCA, % Penetration depth</p><p style="padding-left: 250pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="295" height="1" alt="image" src="Image_007.png"/></span></p><p class="s26" style="padding-top: 1pt;padding-left: 250pt;text-indent: 0pt;text-align: left;">10-15 Epidermis</p><p class="s26" style="padding-left: 250pt;text-indent: 0pt;text-align: left;">15-30 Epidermis</p><p class="s26" style="padding-left: 250pt;text-indent: 0pt;text-align: left;">35 Superficial papillary dermis</p><p class="s26" style="padding-bottom: 3pt;padding-left: 313pt;text-indent: -62pt;line-height: 106%;text-align: left;">50-100 Approaching and reaching upper reticular dermis with increased risk of complications; appropriate for focal use only</p><p style="padding-left: 250pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="295" height="1" alt="image" src="Image_008.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;">observations. This first article in this continuing medical education series about chemical peels discusses superficial and medium-depth peels, including descriptions of the histologic effects and treatment indications of these peels.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">HISTOLOGY</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Key points</p><p class="s27" style="padding-left: 5pt;text-indent: 0pt;line-height: 12pt;text-align: left;">d <span class="s21">Superficial peels induce epidermal injury</span></p><p class="s27" style="padding-left: 14pt;text-indent: -9pt;line-height: 88%;text-align: left;">d <span class="s21">Medium-depth peels penetrate into or through the papillary dermis</span></p><p style="padding-top: 7pt;padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;">Superficial peels produce injury limited to the epidermis, whereas medium-depth peels produce injury into or through the papillary dermis. Indications for superficial peels therefore include mild acne and epidermal and mixed melasma, whereas indications for medium-depth peels include actinic keratosis, lentigines, sallow discoloration, and fine, static wrinkles.</p><p style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;">Common superficial peels include glycolic acid (GA), salicylic acid (SA), Jessner solution (JS), retinoic acid, lactic acid, mandelic acid, pyruvic acid (PA), and trichloroacetic acid (TCA) 10% to 35%. Of these, only GA and PA peels require neutralization, either by sodium bicarbonate or by removal with water. Superficial peels include alpha- and beta-hydroxy acids. Alpha-hydroxy acids, such as glycolic acid, are water soluble. Beta-hydroxy acids, such as salicylic acid, are lipid soluble.</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark51" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Common medium-depth peels include 70% glycolic acid plus 35% TCA, JS plus 35% TCA, solid CO2 plus 35% TCA, and 88% phenol.</a>2-4 <a href="#bookmark52" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Eighty-eight percent phenol is rarely used as a solo agent for large areas because of the risk of cardiotoxicity.</a><a href="#bookmark52" class="s5">5,6</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">SUPERFICIAL PEELS</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: justify;">Key points</p><p class="s27" style="padding-left: 14pt;text-indent: -9pt;line-height: 88%;text-align: justify;">d <span class="s21">Tretinoin, salicylic acid, Jessner solution, and modified Jessner solution do not require neutralization</span></p><p class="s27" style="padding-left: 14pt;text-indent: -9pt;line-height: 89%;text-align: justify;">d <span class="s21">Glycolic and pyruvic acid require neutralization</span></p><p class="s21" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Tretinoin peels</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark53" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Because its solutions in organic solvents are essentially non-acidic as they have no measurable pH, and intranuclear mechanism of action, all-trans retinoic acid or tretinoin peels cause minimal discomfort during application. Tretinoin 5% to 10% peels left on as a 6-hour facial mask cause mild erythema and desquamation on postpeel day 2.</a><a href="#bookmark53" class="s5">7</a> <a href="#bookmark54" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">A randomized trial on forearm rejuvenation showed that tretinoin 0.05% cream nightly was comparable to 5% tretinoin peel every 2 weeks.</a><a href="#bookmark54" class="s5">8</a> <span style=" color: #000;">Tretinoin peels at varying concentrations may be used to treat acne, although supportive clinical trial data are sparse.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Salicylic acid</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark55" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">SA is a beta-hydroxy acid and a phenolic compound with antiinflammatory,</a><a href="#bookmark55" class="s5">9</a> <a href="#bookmark56" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">antimicrobial,</a>10 <a href="#bookmark57" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">and depigmenting properties.</a><a href="#bookmark57" class="s5">11</a> <a href="#bookmark58" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">It is safe in skin of all Fitzpatrick phototypes.</a><a href="#bookmark58" class="s5">12</a> <a href="#bookmark59" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Because of SA’s lipophilic and comedolytic effects, it is particularly effective for comedonal acne.</a>13 <span style=" color: #000;">SA 20% to 30% in ethanol (hydroalcoholic vehicle [HA]) crystallizes upon ethanol evaporation, yielding a pseudofrost that can be removed from the skin with a facewash or wet cloth, if desired. The crystals cannot penetrate the skin; the peel is thus self-limiting.</span></p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark59" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Some patients develop SA-HA hot spots, or areas of overpenetration that may result in postinflamma- tory hyperpigmentation (PIH). In response, a polyethylene glycol (PEG) vehicle was developed that slows delivery while simultaneously increasing follicular penetration.</a><a href="#bookmark59" class="s5">13,14</a> <span style=" color: #000;">Typically, the SA-PEG peel</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a name="bookmark5">is left on the skin for </a><span class="s24">$</span><a href="#bookmark59" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">5 minutes to allow for follicular penetration, and then rinsed off with water as the PEG vehicle is occlusive. A split-face study for acne showed superiority of 30% SA-PEG to 30% SA-HA.</a><span style=" color: #007FAC;">13 </span>SA-HA peels yield mild desquamation after 2 days. In contrast, SA-PEG usually does not cause desquamation. Salicylic acid peels may cause urticaria and angioedema, with known cross-sensitivity to acetylsalicylic acid.<a name="bookmark6">&zwnj;</a><a name="bookmark7">&zwnj;</a><a name="bookmark8">&zwnj;</a><a name="bookmark9">&zwnj;</a><a name="bookmark10">&zwnj;</a><a name="bookmark11">&zwnj;</a><a name="bookmark12">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Trichloroacetic acid</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark61" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">TCA is highly water soluble, with no crystalliza- tion in up to 90% TCA solution.</a>15 <a href="#bookmark62" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">The currently accepted standard preparation of TCA is weight to volume.</a>16 <a href="#bookmark62" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Other preparation methods, such as weight to weight, grams of TCA per 100 mL water, and 100% TCA diluted to lower percentages can result in increased TCA concentrations and complications.</a><a href="#bookmark62" class="s5">16</a></p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;text-align: justify;"><a href="#bookmark39" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Depth    of    penetration    correlates    directly    to concentration  (</a><a href="#bookmark39" class="s5">Table  </a>I<a href="#bookmark63" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">).</a>17  <span style=" color: #000;">TCA  </span><span class="s28">[</span><a href="#bookmark64" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">35%  is  used  for focal    treatment    of    individual    lesions    because pigmentary  complications  and  scars  are  common with use over large areas. TCA penetrates slowly, so one must wait at least 5 minutes to assess the frosting endpoint  and  to  avoid  overcoating.</a>18  <a href="#bookmark40" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">There  are  3 levels  of  frosting:  1)  a  light  reticular  frost  with background  erythema,  2)  a  confluent  light  white frost with background erythema, and 3) a solid white frosting without erythema (</a><a href="#bookmark40" class="s5">Fig </a>1<span style=" color: #000;">). Frosting seen with TCA corresponds to epidermal and dermal protein denaturation.</span></p><p style="padding-left: 5pt;text-indent: 11pt;text-align: justify;">TCA <span class="s28">[</span><a href="#bookmark65" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">80% is only appropriate for focal use,</a><a href="#bookmark65" class="s5">19</a> as in the following examples.</p><p class="s21" style="padding-left: 15pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Mild to moderate rhinophyma. <span class="p">Chemical</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark66" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">cauterization compares favorably to electro- coagulation, with excellent safety over a 5-decade experience.</a><a href="#bookmark66" class="s5">20</a></p><p class="s21" style="padding-left: 15pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Chemical reconstruction of skin scars. <span class="p">Focal</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark67" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">ice pick or boxcar acne scar treatment increases collagen deposition and decreases scar depth.</a><a href="#bookmark67" class="s5">21-26</a></p><p class="s21" style="padding-left: 15pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Earlobe tears. <a href="#bookmark68" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">TCA 90%</a><span class="s14">27,28 </span><span class="p">creates epidermal</span></p><p class="s14" style="padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark41" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">and dermal necrosis allowing second intent reapproximation (</a>Fig 2<span style=" color: #000;">).</span></p><p class="s21" style="padding-left: 15pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">Xanthelasma. <span class="p">For xanthelasma, vary TCA</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;">strength based on morphology<span class="s24">d</span><a href="#bookmark69" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">macular lesions may be treated with TCA 50%, whereas papular lesions require TCA 70% to 100%.</a><a href="#bookmark69" class="s5">29-31</a></p><p class="s21" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Jessner and modified Jessner solution</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark63" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">JS consists of 14% resorcinol, 14% SA, and 14% lactic acid (LA) in 95% ethanol.</a>17 <span style=" color: #000;">The application of modified JS (MJS) is shown in </span>Supplementary Video 1 <a href="https://www.jaad.org/" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;" target="_blank">(available online at </a>https://www.jaad.org<span style=" color: #000;">). Resorcinol, which acts similarly to hydroquinone</span></p><p class="s14" style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark70" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">(meta- and para-dihydroxybenzene, respectively), may cause contact allergy and risks inducing cross-sensitivity with hydroquinone with repeated exposure.</a><a href="#bookmark70" class="s5">32</a> <a href="#bookmark62" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">In response, Bridenstine and Dolezal</a>16 <span style=" color: #000;">modified MJS by increasing the concentration of SA</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 92%;text-align: left;">and LA to 17% and replacing resorcinol with 8% citric <a href="#bookmark70" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt; vertical-align: -4pt;">acid.</a><a href="#bookmark70" class="s30">32,33</a></p><p style="padding-top: 1pt;padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark71" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">A study comparing JS plus 20% TCA versus 20% TCA alone in individuals with higher Fitzpatrick skin phototypes found that JS plus 20% TCA was more effective in treating melasma but with greater immediate discomfort. There was no significant difference in PIH.</a><a href="#bookmark71" class="s5">34,35</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Glycolic acid and pyruvic acid</p><p style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;">GA is a water-soluble, alpha-hydroxy acid and PA is an alpha-keto acid. To avoid overpenetration, GA and PA must be neutralized as soon as the clinical endpoint of erythema is reached, or after 5 minutes if no erythema is present. These acids can be neutralized with 10% sodium bicarbonate, with water, or by wiping with a saline-dampened cloth. Both agents are safe at low concentrations (GA 50%/PA 40%); however, at GA 70% and PA 50%, both risk focal irritation or hot spots.</p><p style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;">Sometimes erythema, which is the endpoint for neutralization, quickly progresses to frosting. This rapid transition is associated with scar or PIH and, consequently, a shift toward safer alternatives, such as SA, MJS, or low-strength GA, has occurred.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">MEDIUM DEPTH PEELS</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Key points</p><p class="s27" style="text-indent: 0pt;line-height: 88%;text-align: right;">d <span class="s21">TCA 50% risks scarring and dyspigmentation </span>d <span class="s21">Safer medium-depth peels include solid CO2 plus TCA 35%, JS plus TCA 35%, and GA 70%</span></p><p class="s21" style="padding-left: 14pt;text-indent: 0pt;line-height: 12pt;text-align: justify;">plus TCA 35%</p><p class="s27" style="padding-left: 14pt;text-indent: -9pt;line-height: 89%;text-align: justify;">d <span class="s21">88% phenol is a medium-depth peel, but hypopigmentation and cardiotoxicity are risks</span></p><p class="s27" style="padding-left: 14pt;text-indent: -9pt;line-height: 89%;text-align: justify;">d <span class="s21">Medium-depth peels should not be performed off the face and scalp</span></p><p style="padding-top: 7pt;padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;">Medium-depth peels penetrate and induce histologic changes within the papillary dermis. Historically, medium-depth peels were performed using TCA 50%, yielding uneven penetration and erosions, PIH, and scars. As a result, researchers Harold Brody, Gary Monheit, and William Coleman introduced the use of a physical or chemical agent to induce epidermolysis before the application of TCA 35% and thereby allow for its safe, predictable, even penetration.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><span><img width="622" height="309" alt="Image of Fig 1" title="Image of Fig 1" src="Image_009.jpg"/></span></p><p class="s31" style="padding-top: 2pt;padding-left: 59pt;text-indent: 0pt;text-align: justify;"><a name="bookmark13">Fig 1. A</a><span class="s23">, Level I frost showing a light reticular frost with background erythema. </span>B<span class="s23">, Level II frost showing a confluent light white frost with background erythema. </span>C<span class="s23">, Level III frost showing a solid white frosting without erythema.</span><a name="bookmark14">&zwnj;</a><a name="bookmark40">&zwnj;</a><a name="bookmark41">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="478" height="150" alt="Image of Fig 2" title="Image of Fig 2" src="Image_010.jpg"/></span></p><p class="s31" style="padding-top: 2pt;padding-left: 59pt;text-indent: 0pt;text-align: left;">Fig 2. <span class="s23">Earlobe cleft treated with 2 sessions of 100% trichloroacetic acid administered 1 month apart.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s14" style="padding-top: 3pt;padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark72" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Medium-depth peels share similar histologic effects: at day 3 postpeel, there is full-thickness epidermal necrosis, a dermal inflammatory infiltrate, and papillary dermal edema.</a>36 <a href="#bookmark73" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">At day 7, the epidermis reepithelializes.</a>37 <a href="#bookmark72" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">At day 30, there is regeneration of homogenized collagen.</a>36-38 <a href="#bookmark75" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">At day 90, thickened collagen bundles are present in the dermis showing a Grenz zone overlying a reticular elastotic band, the thickness proportional to the strength of the peel.</a>39 <a href="#bookmark76" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Type I collagen is also markedly increased.</a><a href="#bookmark76" class="s5">40</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Brody peel: Solid CO2 (dry ice) plus TCA 35%</p><p class="s24" style="text-indent: 0pt;line-height: 10pt;text-align: left;">—</p><p style="text-indent: 0pt;text-align: left;"/><p style="padding-left: 5pt;text-indent: 11pt;text-align: justify;">This approach combines solid CO2 (dry ice) and TCA to create a controlled medium-depth peel. Solid CO2 ( 78.5<span class="s24">8</span>C) is available from local supermarkets, ice cream manufacturers, or pharmaceutical supply companies, food supply, or food bait packing plants.</p><p class="s14" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><span style=" color: #000;">After degreasing the face with acetone, handheld blocks of solid CO2 are dipped in a 3:1 acetone to alcohol solution, allowing the CO2 to glide smoothly over the skin  (</span>Supplementary Video 2<a href="https://www.jaad.org/" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;" target="_blank">; available online at </a>https://www.jaad.org<a href="#bookmark40" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">). The application time of solid CO2 ranges from 3 to 15 seconds, allowing for superficial to deep penetration of TCA. The endpoint of solid CO2 application is transient white frost with residual erythema. Afterwards, TCA 35% is applied until an endpoint of even light white or solid white frost is achieved (</a>Fig 1<span style=" color: #000;">; </span>Supplementary Video 2<a href="#bookmark73" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">).</a>37 <a href="#bookmark40" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">TCA causes epidermal and dermal protein denaturation corresponding to the clinically observed frost (</a><a href="#bookmark40" class="s5">Fig </a>1<span style=" color: #000;">).</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Monheit peel: JS plus 35% TCA</p><p style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: left;">This peel uses JS as a keratolytic agent to further TCA penetration and is performed by degreasing the</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="478" height="176" alt="Image of Fig 3" title="Image of Fig 3" src="Image_011.jpg"/></span></p><p class="s31" style="padding-top: 2pt;padding-left: 59pt;text-indent: 0pt;line-height: 107%;text-align: justify;"><a name="bookmark15">Fig 3. </a><span class="s23">Before and 8 months after a medium-depth CO2 hard plus trichloroacetic acid 35% peel on a Glogau photoaging IV female who was not a candidate for a deep peel showing a substantial reduction and removal of wrinkles, pigmentation, and actinic keratoses with medium-depth wounding.</span><a name="bookmark42">&zwnj;</a><a name="bookmark43">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="478" height="318" alt="Image of Fig 4" title="Image of Fig 4" src="Image_012.jpg"/></span></p><p class="s31" style="padding-top: 2pt;padding-left: 59pt;text-indent: 0pt;line-height: 107%;text-align: justify;">Fig 4. <span class="s23">Segmental combination peel using medium-depth and deep peels. The perioral and glabella areas were treated with a deep peel of 1.2% croton oil in 35% phenol. The periocular area was treated with a medium-depth peel with straight 88% phenol without croton oil. The rest of the face was treated with a medium-depth peel with Jessner solution plus 35% trichloroacetic acid to blend skin color and texture. Liquid nitrogen was applied to larger lentigines.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s14" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark77" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">face with acetone followed by the application of JS until a reticulate frost is obtained.</a>41,42 <a href="#bookmark79" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">MJS can be used alternatively in darker skin to treat pigmenta- tion and has less risk of contact sensitivity.</a>43-45 <a href="#bookmark80" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Although contact allergy to resorcinol is rare, it may be underreported.</a><a href="#bookmark80" class="s5">46</a> <span style=" color: #000;">TCA is applied after MJS/JS until the desired endpoint is obtained. JS plus TCA 20% may be used, but may not create a significant medium-depth wound and is unstudied.</span></p><p class="s21" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Coleman peel: GA 70% plus TCA 35%</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark75" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">In this peel, degreasing with acetone is unnecessary if patients are not wearing make-up or other products. Patients are asked to wash their faces with soap before procedure. GA 70% is first applied for approximately 2 minutes with an endpoint of erythema, then removed with water. Next, TCA 35% is applied until the endpoint is reached.</a>39 <a href="#bookmark74" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Tse et al</a>38 <span style=" color: #000;">compared JS plus TCA 35%</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="478" height="176" alt="Image of Fig 5" title="Image of Fig 5" src="Image_013.jpg"/></span></p><p class="s31" style="padding-top: 2pt;padding-left: 59pt;text-indent: 0pt;line-height: 107%;text-align: justify;"><a name="bookmark16">Fig 5. </a><span class="s23">Segmental combination peel using medium-depth and deep peels. The perioral areas were treated with a deep peel of 1.2% croton oil in 35% phenol. The rest of the face was treated with a medium-depth peel of CO2 plus 35% trichloroacetic acid. The neck was treated with a superficial peel with 20% trichloroacetic acid.</span><a name="bookmark17">&zwnj;</a><a name="bookmark18">&zwnj;</a><a name="bookmark44">&zwnj;</a><a name="bookmark45">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 29pt;text-indent: 0pt;text-align: left;"><span><img width="231" height="173" alt="Image of Fig 6" title="Image of Fig 6" src="Image_014.jpg"/></span></p><p class="s31" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;">Fig 6. <span class="s23">Hypopigmentation of the left cheek 6 months after 88% phenol peel.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark75" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">and GA 70% plus TCA 35%, finding that the latter induced greater neoelastogenesis. Conversely, JS plus TCA 35% exhibited greater neovascularization and papillary dermal fibrosis. In their study of 13 patients, those receiving the GA 70% plus TCA 35% peel noted more pain immediately after GA application.</a><a href="#bookmark75" class="s5">39</a></p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark42" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">By way of comparison, solid CO2 plus TCA is histologically the deepest peel, improving wrinkles when performed to a solid white frost (</a>Fig 3<a href="#bookmark72" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">). Unless a medium-depth peel penetrates the entire papillary dermis, it cannot maximize its potential results; JS and GA followed by TCA may be less capable of reaching that histologic endpoint.</a>36,38 <span style=" color: #000;">Solid CO2 followed by TCA is easier for the patient to tolerate than JS or GA followed by TCA, which exemplify an acid followed by another acid, producing more patient discomfort. Analgesia is unnecessary for any medium-depth peel if the operator is experienced in performing the peel rapidly and smoothly. Medium-depth peels should not be used elsewhere than on the face or the scalp because of the risk of scarring.</span></p><p class="s21" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Segmental peeling</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><span style=" color: #000;">A segmental peel uses different peeling agents on different cosmetic units to tailor the wounding agent to  the  degree  of  photodamage.  Not  uncommonly, the perioral or the periorbital area exhibits Glogau III or  IV  wrinkles  while  the  remainder  of  the  face exhibits   only   mild   sun   damage.   The   use   of   a phenol/croton oil formula on one or two cosmetic units, equivalent to a body surface area of </span><span class="s28">\</span><a href="#bookmark43" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">2%, does not require cardiac monitoring if each cosmetic unit is peeled over 10 to 15 minutes. The second article in    this    continuing    medical    education    series discusses   phenol/croton   oil   peels.   Performing   a medium-depth   peel   adjacent   to   the   deep   peel prevents a line of demarcation, blends, and unifies the  rejuvenation  effect  (</a><a href="#bookmark43" class="s5">Figs  </a>4  <a href="#bookmark44" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">and  </a>5<span style=" color: #000;">).  Regional anesthesia  with  nerve  blocks,  oral  hydration,  and oral benzodiazepines increase patient comfort.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Phenol</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark45" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Unoccluded 88% phenol is a medium-depth peel and is rarely used for full-face peeling because of the risks of cardiotoxicity and hypopigmentation (</a>Fig 6<a href="#bookmark81" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">).</a>47,48 <a href="#bookmark82" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Phenol immediately coagulates epidermal and superficial dermal proteins</a>49 <a href="#bookmark83" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">with increased collagen and elastic fibers histologically.</a>50 <a href="#bookmark83" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">A punctuated 88% phenol technique to individual rhytids has been described and decreases phenol exposure.</a><a href="#bookmark83" class="s5">50</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">APPLICATION TECHNIQUES</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Key point</p><p class="s27" style="padding-left: 14pt;text-indent: -9pt;line-height: 89%;text-align: left;">d <span class="s21">Chemical peels can be applied with brushes, gauze, or cotton-tipped applicators</span></p><p style="padding-top: 7pt;padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;">Chemical peels can be applied with a sable or goat hair brush or with a gauze or cotton-tipped</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="478" height="133" alt="Image of Fig 7" title="Image of Fig 7" src="Image_015.jpg"/></span></p><p class="s31" style="padding-top: 2pt;padding-left: 59pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a name="bookmark19">Fig 7. </a><span class="s23">(Left) Erythematous rolling acne scars on the forehead. (Middle) Three days after application of a medium-depth peel with CO2 plus 35% trichloroacetic acid. (Right) Six weeks after treatment with a medium-depth chemical peel.</span><a name="bookmark20">&zwnj;</a><a name="bookmark21">&zwnj;</a><a name="bookmark22">&zwnj;</a><a name="bookmark23">&zwnj;</a><a name="bookmark24">&zwnj;</a><a name="bookmark46">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;">applicator. For superficial peeling agents, brushes that can be cleaned with soap and water provide rapid application with little waste. Gauze or cotton absorbs and therefore wastes more solution when the applicator is discarded.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 81%;text-align: justify;">COMMON INDICATIONS FOR SUPERFICIAL AND MEDIUM PEELS</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: justify;">Key points</p><p class="s27" style="padding-left: 14pt;text-indent: -9pt;line-height: 89%;text-align: justify;">d <span class="s21">Chemical peels are safe and effective for several medical and cosmetic indications</span></p><p class="s21" style="padding-left: 14pt;text-indent: -9pt;line-height: 89%;text-align: justify;"><span class="s27">d </span>Medium-depth peels reduce p53 mutations in ultraviolet light<span class="s24">e</span>irradiated mice and actinic keratosis count</p><p class="s21" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Acne</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;text-align: justify;"><a href="#bookmark84" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Superficial chemical peels are effective for mild to moderate acne.</a>51-54 <a href="#bookmark86" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">SA 30% and GA 30% were similarly effective in a split-face randomized control trial.</a><a href="#bookmark86" class="s5">55</a> <span style=" color: #000;">In darker skin types, superficial peels are safe and effective in reducing papule, pustule, and comedone count. One study found that SA or salicylic</span><span class="s24">e</span><a href="#bookmark87" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">mandelic acid peels were better than GA peels.</a><a href="#bookmark87" class="s5">56</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Acne scars</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark46" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Acne scars are categorized into icepick, boxcar, or rolling scars (</a>Fig 7<a href="#bookmark88" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">).</a><a href="#bookmark88" class="s5">57</a> <a href="#bookmark73" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Medium-depth chemical peels using solid CO2 slush with focal 50% TCA to efface scar rims</a><a href="#bookmark73" class="s5">37</a> <a href="#bookmark89" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">or JS followed by 35% TCA may improve acne scars in lighter skin types. Focal dermabrasion may follow the peel.</a>58 <span style=" color: #000;">Chemical reconstruction of skin scars is discussed in the second article in this continuing medical education series.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Actinic keratosis</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark90" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Medium-depth chemical peel penetration into the papillary dermis supports its use in treatment of actinic keratosis.</a><a href="#bookmark90" class="s5">59</a> <span style=" color: #000;">In a split-face comparison using one application of JS plus 35% TCA versus topical 5-flurouracil (5-FU) twice daily for 3 weeks, both</span></p><p class="s14" style="padding-top: 3pt;padding-left: 6pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark91" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">groups achieved a 75% reduction in AK. Skin biopsy specimens showed a similar decrease in keratinocyte atypia.</a>60 <a href="#bookmark92" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Long-term efficacy of JS plus 35% TCA is similar to that of 5-flurouracil, with sustained improvement at 12 months of follow-up.</a>61 <a href="#bookmark93" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">For actinic cheilitis, one application of 50% TCA yields a median time to recurrence of 9 months, but is inferior to 5-flurouracil 3 times daily for 2 weeks, shave removal, and CO2 laser ablation.</a>62 <span style=" color: #000;">Consequently, 50% TCA chemical is not recommended for actinic cheilitis, except in patients compliant with follow-up.</span></p><p class="s14" style="padding-left: 6pt;text-indent: 11pt;text-align: justify;"><a href="#bookmark94" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Chemical peels may prevent photocarcinogen- esis.</a><a href="#bookmark94" class="s5">63</a> <span style=" color: #000;">SA-PEG suppressed keratinocyte expression of p53 protein in ultraviolet B light</span><span class="s24">e</span><a href="#bookmark60" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">irradiated mice. In vivo experiments in human facial skin showed that SA normalizes keratinocyte differentiation.</a>14 <span style=" color: #000;">In another study in ultraviolet light</span><span class="s24">e</span><a href="#bookmark95" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">irradiated hairless mice, 35% GA, 30% SA, and 10% or 35% TCA suppressed p53 mutations, reduced messenger RNA expression of cyclooxy- genase 2, and decreased serum concentrations of prostaglandin E2, leading to decreased tumor formation.</a><a href="#bookmark95" class="s5">64,65</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">Infraorbital hyperpigmentation</p><p style="padding-left: 5pt;text-indent: 12pt;text-align: justify;">Infraorbital  darkening  has  a  multifactorial  etiol- ogy,  including  hyperpigmentation,  periorbital  fat pseudoherniation,   fine   wrinkling,   and   reticular veins. Chemical peels are ineffective for pseudoher- niation and veins, but microneedling combined with 10% TCA improved hyperpigmentation in <span class="s28">[</span><a href="#bookmark96" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">90% of patients.</a><span style=" color: #007FAC;">66  </span>Four  weekly  3.75%  TCA  and  15%  lactic acid  peels  resulted  in  excellent  improvement  in <span class="s28">[</span><a href="#bookmark97" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">90%  of  patients  at  6  months  of  follow-up.</a><span style=" color: #007FAC;">67  </span><a href="#bookmark98" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">GA 20%  and  lactic  acid  15%  showed  73%  and  56% improvement in periorbital melanosis.</a><a href="#bookmark98" class="s5">68</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 6pt;text-indent: 0pt;text-align: left;">Melasma</p><p style="padding-left: 6pt;text-indent: 11pt;line-height: 106%;text-align: justify;">Melasma disproportionately affects darker Fitzpatrick skin phototypes; therefore, laser or</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 59pt;text-indent: 0pt;text-align: left;"><span><img width="478" height="360" alt="Image of Fig 8" title="Image of Fig 8" src="Image_016.jpg"/></span></p><p class="s31" style="padding-top: 2pt;padding-left: 59pt;text-indent: 0pt;line-height: 107%;text-align: justify;"><a name="bookmark25">Fig 8. </a><span class="s23">(</span>A<span class="s23">) Before and (</span>B<span class="s23">) after treatment of melasma. The patient was treated with superficial peels using salicylic acid 20% for 1 session, salicylic acid 30% for 1 session, and then tretinoin 1% for 1 session. Each session was performed 4 weeks apart. (Photographs courtesy of Pearl Grimes, MD.)</span><a name="bookmark26">&zwnj;</a><a name="bookmark27">&zwnj;</a><a name="bookmark47">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s14" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark99" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">deep peels present a risk for PIH. Superficial peels in combination with hydroquinone offer a safe alternative. In a randomized study of 40 Indian patients, Sarkar et al</a>69 <span style=" color: #000;">compared hydroquinone 2%, tretinoin 0.05% cream, and hydrocortisone 1% cream to 6 30% GA peels performed every</span></p><p class="s14" style="padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark99" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">3 weeks. The GA group showed significant improvement compared to bleaching cream only.</a>69 <a href="#bookmark47" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Other clinical studies document the efficacy of LA, JS, and tretinoin peels for melasma (</a>Fig 8<a href="#bookmark100" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">).</a><a href="#bookmark100" class="s5">70-72</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Postinflammatory hyperpigmentation</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;text-align: justify;"><a href="#bookmark58" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Chemical peels increase epidermal turnover and decrease epidermal melanin. Grimes</a><a href="#bookmark58" class="s5">12</a> <span style=" color: #000;">pretreated 5 patients  with  PIH  with  hydroquinone  4%  before treatment  with  a  series  of  5  SA  20%  to  30%  peels every  2  weeks:  80%  had </span><span class="s28">[</span><a href="#bookmark58" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">75%  improvement,  and 20%  had  51%  to  75%  improvement  in  PIH.</a>12  <a href="#bookmark101" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Joshi et al</a><a href="#bookmark101" class="s5">73</a> <span style=" color: #000;">replicated these findings using a randomized split-face  model,  in  which  10  subjects  with  PIH received  SA  20%  to  30%  peels  on  half  of  the  face, and no treatment on the other half.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Photorejuvenation</p><p style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;">Medium-depth peels induce histologic and clinical improvement in parameters of photoaging,</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 29pt;text-indent: 0pt;text-align: left;"><span><img width="231" height="185" alt="Image of Fig 9" title="Image of Fig 9" src="Image_017.jpg"/></span></p><p class="s23" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: justify;"><a name="bookmark48"><span class="s31">Fig 9. </span></a>Herpes simplex virus outbreak of the left cheek at day 4 after a JS <span class="s26">1 </span>35% trichloroacetic acid peel.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="#bookmark78" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">in particular lentigines, fine wrinkles, sallow discoloration, and actinic keratosis directly related to peel depth.</a><a href="#bookmark78" class="s5">42,74</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">PRE- AND POSTPEEL PREPARATION</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s2" style="padding-left: 5pt;text-indent: 0pt;line-height: 14pt;text-align: left;">Key points</p><p class="s27" style="padding-left: 14pt;text-indent: -9pt;line-height: 89%;text-align: left;">d <span class="s21">Topical tretinoin improves penetration and decreases healing time</span></p><p class="s27" style="padding-left: 14pt;text-indent: -9pt;line-height: 89%;text-align: left;">d <span class="s21">Wet soaks and emollients are recommended for reepithelialization</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-top: 2pt;padding-bottom: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="bookmark28">Table II. </a><span class="s24">Postpeel prophylaxis before medium-depth peels</span><a name="bookmark29">&zwnj;</a><a name="bookmark30">&zwnj;</a><a name="bookmark49">&zwnj;</a></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="622" height="1" alt="image" src="Image_018.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><span><img width="622" height="1" alt="image" src="Image_019.png"/></span></p><p class="s25" style="padding-top: 2pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Timeframe Action taken</p><p class="s26" style="padding-top: 3pt;padding-left: 14pt;text-indent: -9pt;line-height: 106%;text-align: left;">2-4 weeks prepeel preparation</p><p class="s26" style="padding-top: 3pt;padding-left: 14pt;text-indent: -9pt;line-height: 106%;text-align: left;">Topical tretinoin over moisturizer (stop tretinoin 1 week before peel in patients with Fitzpatrick skin phototypes IV-VI)</p><p class="s26" style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Moisturizer</p><p class="s26" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Day of procedure Valacyclovir 1 g twice daily for 7 days</p><p class="s26" style="padding-left: 100pt;text-indent: -95pt;line-height: 106%;text-align: left;">Postprocedure White petrolatum 3 times daily for 3 days, may change to emollient cream 3 times daily on day 4 Pain, malaise, pustules: bacterial culture, empiric trimethoprim-sulfamethoxazole twice daily, and</p><p class="s26" style="padding-left: 109pt;text-indent: 0pt;text-align: left;">gentamycin 0.1% cream 3 times daily for 7 days</p><p class="s26" style="padding-left: 100pt;text-indent: 0pt;line-height: 106%;text-align: left;">Itch, pustules: candidal culture; empiric fluconazole 200 mg 3 1 dose Induration: topical or intralesional steroid</p><p class="s26" style="padding-left: 100pt;text-indent: 0pt;text-align: left;">Sun protection</p><p class="s26" style="padding-left: 100pt;text-indent: 0pt;text-align: left;">Do not pick at or peel exfoliative skin</p><p class="s26" style="padding-bottom: 3pt;padding-left: 109pt;text-indent: -9pt;line-height: 106%;text-align: left;">If not healed in 7 days, consider complications. If HSV infection is suspected, start treatment dose of valcyclovir 1 g 3 times daily for 7 days</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="622" height="1" alt="image" src="Image_020.png"/></span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s27" style="padding-top: 3pt;padding-left: 14pt;text-indent: -9pt;line-height: 89%;text-align: left;">d <span class="s21">Herpes simplex virus prophylaxis is warranted</span></p><p class="s21" style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Prepeel</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;text-align: justify;"><span style=" color: #000;">Sun protection before and after the peel is mandatory. Medium-depth peels are not recommen- ded for Fitzpatrick skin phototypes </span><span class="s24">$</span><a href="#bookmark64" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">IV because of the risk of PIH.</a>18 <a href="#bookmark102" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">This risk may be reduced by prepeel preparation with hydroquinone for 1 month</a><a href="#bookmark102" class="s5">75</a> <a href="#bookmark85" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">and peeling during the winter season.</a><a href="#bookmark85" class="s5">54</a></p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark103" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">For superficial and medium peels, pretreatment with topical tretinoin for 2 to 4 weeks enables a more uniform frosting and improves healing time.</a>76 <span style=" color: #000;">For Fitzpatrick skin phototypes IV to VI, expert consensus recommends tretinoin cessation 1 week before the peel to prevent overpenetration</span></p><p style="padding-left: 48pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><a href="#bookmark104" class="s30">77,78</a></p><p style="padding-top: 7pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;">point a physical sunscreen can be applied. Patients should be discouraged from picking at or peeling exfoliative skin.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Complications</p><p style="padding-left: 5pt;text-indent: 11pt;text-align: justify;">To prevent ocular exposure, solutions should not be passed over the eyes during the procedure, and saline eyewash bottles should be immediately available. Complications of medium depth peels include prolonged erythema, scarring, hypo- or hyperpigmentation, and infections. Common infec- tions include <span class="s32">Candida albicans</span>, <span class="s32">Staphylococcus aureus</span>, <span class="s32">Pseudomonas aeruginosa</span>, and herpes simplex virus. Prolonged erythema can be related to irritant or allergic contact dermatitis or to</p><p class="s14" style="padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: justify;"><a href="#bookmark80" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">overpenetration.</a>46 <span style=" color: #000;">Prolonged erythema may be</span></p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">and PIH.</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">Pretreatment for 2 weeks with</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 8pt;text-align: left;">treated with pulsed-dye or dual wavelength vascular</p><p style="padding-left: 5pt;text-indent: 0pt;line-height: 10pt;text-align: left;">hydroquinone 2% is more effective than tretinoin</p><p style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a href="#bookmark105" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">0.025% in decreasing PIH.</a><a href="#bookmark105" class="s5">79,80</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s21" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">Postpeel</p><p style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;">Postpeel management focuses on expediting healing and preventing infection. For edema and mild discomfort, ice packs can be used. Gently soaking and cleansing the skin followed by application of white petrolatum for 3 days enables reepithelialization; afterward, patients may continue petrolatum or switch to an emollient cream.</p><p class="s14" style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;"><a href="#bookmark106" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Patients with a history of herpes simplex virus should receive prophylactic antiviral medication for 7 days postprocedure until completely reepithelial- ized.</a><a href="#bookmark106" class="s5">78</a> <a href="#bookmark48" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">Herpes simplex virus infection often presents on day 2 or 3 when reepithelialization commences, with increased pain, itch, or discomfort (</a><a href="#bookmark48" class="s5">Fig </a>9<a href="#bookmark49" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 10pt;">). Pustules suggest bacterial or candidal infection and warrant culture and initiation of empiric therapy (</a><a href="#bookmark49" class="s5">Table </a>II<span style=" color: #000;">).</span></p><p style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;">Sun protection is paramount. Physical barriers should be used until reepithelialization, at which</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 106%;text-align: justify;">lasers. For incipient scarring, topical or intralesional steroids may be initiated.</p><p style="padding-left: 5pt;text-indent: 11pt;line-height: 106%;text-align: justify;">In conclusion, superficial and medium-depth peels can treat a variety of conditions, including dyschromia, keratinocyte dysplasia, acne, and acne scarring. Careful patient and peel selection will ensure procedural success with excellent results. For the novice peeler, starting with superficial peels on Fitzpatrick skin phototypes I and II will help the peeler gain comfort with the acids, applicator types, and techniques with minimal adverse side effects. The difference between satisfactory versus excellent results depends on the selection of the proper peeling agents and the understanding of gentle versus aggressive application technique during their use. Though artistry and the appreciation of preserving skin integrity is important, relying on the science that we have learned and are researching now is crucial to duplicating our results and preserving this art for the generations of dermatologists ahead of us.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s23" style="padding-top: 4pt;padding-left: 5pt;text-indent: 11pt;line-height: 108%;text-align: justify;"><a href="http://www.peelingsociety.com/home/" style=" color: black; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt;" target="_blank" name="bookmark31">We thank Pearl Grimes, MD, for her contribution of photographs for this manuscript and the reviewers and the members of the International Peeling Society (</a><span style=" color: #007FAC; font-family:Garamond, serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 9pt;">http://www.peelingsociety.com/home/</span>) for their diligence in compiling and reviewing this article.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s34" style="padding-left: 5pt;text-indent: 0pt;text-align: left;"><a name="bookmark50">REFERENCES</a></p><ol id="l1"><li><p class="s18" style="padding-left: 19pt;text-indent: -9pt;line-height: 107%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref1" class="a" target="_blank" name="bookmark51">Brody HJ, Monheit GD, Resnik SS, Alt TH. A history of chemical peeling. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref1" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref1" class="a" target="_blank">. </a>2000;26:405-409<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -9pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref2" class="a" target="_blank">Berson DS, Cohen JL, Rendon MI, Roberts WE, Starker I, Wang B. Clinical role and application of superficial chemical peels in today’s practice. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref2" class="s35" target="_blank">J Drugs Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref2" class="a" target="_blank">. 2009;8: </a>803-811<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -9pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref3" class="a" target="_blank">Fischer TC, Perosino E, Poli F, Viera MS, Dreno B, Cosmetic Dermatology European Expert Group. Chemical peels in aesthetic dermatology: an update 2009. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref3" class="s35" target="_blank">J Eur Acad Dermatol Venereol</a>. 2010;24:281-292<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -9pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref4" class="a" target="_blank" name="bookmark52">Monheit GD. Chemical peels. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref4" class="s35" target="_blank">Skin Therapy Lett</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref4" class="a" target="_blank">. </a>2004;9:6-11<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -9pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref5" class="a" target="_blank">Botta SA, Straith RE, Goodwin HH. Cardiac arrhythmias in phenol face peeling: a suggested protocol for prevention. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref5" class="s35" target="_blank">Aesthet Plast Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref5" class="a" target="_blank">. </a>1988;12:115-117<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -9pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref6" class="a" target="_blank">Gross BG. Cardiac arrhythmias during phenol face </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref6" target="_blank">peeling.</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref6" class="s35" target="_blank" name="bookmark53">Plast Reconstr Surg</a>. 1984;73:590-594<span style=" color: #000;">.</span></p><p style="text-indent: 0pt;line-height: 8pt;text-align: left;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref7">e</a></p><p style="text-indent: 0pt;text-align: left;"/></li><li><p class="s18" style="padding-left: 19pt;text-indent: -9pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref7" class="a" target="_blank" name="bookmark54">Magalhaes G, Borges M, Queiroz A, Capp A, Pedrosa S, Diniz M. Double-blind randomized study of 5% and 10% retinoic acid peels in the treatment of melasma: clinical evaluation and impact on the quality of life. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref7" class="s35" target="_blank">Surg Cosmet Dermatol</a>. 2011;3:17-22<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -9pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref8" class="a" target="_blank" name="bookmark55">Sumita J, Soares J, Tannus F, Miot H, Bagatin E. Tretinoin 5% peeling versus 0.05% cream for advanced photoaging of the forearms: an open, randomized, evaluator-blinded and compar- ative study. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref8" class="s35" target="_blank">J Am Acad Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref8" class="a" target="_blank">. 2017;76(6 suppl </a>1):AB269<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -9pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref9" class="a" target="_blank">Chiabrando C, Castelli MG, Cozzi E, et al. Antiinflammatory </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref9" target="_blank">action</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 107%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref9" class="a" target="_blank" name="bookmark56">of salicylates: aspirin is not a prodrug for salicylate against rat carrageenin pleurisy. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref9" class="s35" target="_blank">Eur J Pharmacol</a>. 1989;159:257-264<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref10" class="a" target="_blank" name="bookmark57">Bandara M, Sankaridurg P, Zhu H, Hume E, Willcox M. Effect of salicylic acid on the membrane proteome and virulence of </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref10" class="s35" target="_blank">Pseudomonas aeruginosa</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref10" class="a" target="_blank">. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref10" class="s35" target="_blank">Invest Ophthalmol Vis Sci</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref10" class="a" target="_blank">. 2016;57: </a>1213-1220<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref11" class="a" target="_blank" name="bookmark58">Chang TS. An updated review of tyrosinase inhibitors. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref11" class="s35" target="_blank">Int J Mol Sci</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref11" class="a" target="_blank">. </a>2009;10:2440-2475<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 107%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref12" class="a" target="_blank" name="bookmark59">Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref12" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref12" class="a" target="_blank">. </a>1999;25:18-22<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref13" class="a" target="_blank" name="bookmark60">Dainichi T, Ueda S, Imayama S, Furue M. Excellent clinical results with a new preparation for chemical peeling in acne: 30% salicylic acid in polyethylene glycol vehicle. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref13" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref13" class="a" target="_blank">. </a>2008;34:891-899<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref14" class="a" target="_blank" name="bookmark61">Dainichi T, Amano S, Matsunaga Y, et al. Chemical peeling by SA-PEG remodels photo-damaged skin: suppressing p53 expression and normalizing keratinocyte differentiation. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref14" class="s35" target="_blank">J Invest Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref14" class="a" target="_blank">. </a>2006;126:416-421<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="https://pubchem.ncbi.nlm.nih.gov/compound/6421" style=" color: black; font-family:Arial, sans-serif; font-style: normal; font-weight: normal; text-decoration: none; font-size: 8pt;" target="_blank" name="bookmark62">National Center for Biotechnology Information website. Com- pound summary. Trichloroacetic acid. Available at: </a><a href="https://pubchem.ncbi.nlm.nih.gov/compound/6421" class="a" target="_blank">https://</a> pubchem.ncbi.nlm.nih.gov/compound/6421<span style=" color: #000;">. Accessed April 12, 2018.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref16" class="a" target="_blank" name="bookmark63">Bridenstine JB, Dolezal JF. Standardizing chemical peel solu- tion formulations to avoid mishaps. Great fluctuations in actual concentrations of trichloroacetic acid. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref16" class="s35" target="_blank">J Dermatol Surg Oncol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref16" class="a" target="_blank">. </a>1994;20:813-816<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref17" class="a" target="_blank">Wambier C, Brody H. Classification of chemical peels. In: da Costa A, ed. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref17" class="s35" target="_blank">Minimally Invasive Aesthetic Procedures for Dermatologists and Plastic Surgeons</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref17" class="a" target="_blank">. Atlanta, GA: Springer Nature; </a>2019:1-12<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-top: 3pt;padding-left: 19pt;text-indent: -13pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref18" class="a" target="_blank" name="bookmark64">Brody HJ. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref18" class="s35" target="_blank">Chemical Peeling and Resurfacing</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref18" class="a" target="_blank">. 3rd ed. Atlanta, GA: Emory University Digital Library Publications;</a> 2009:1-267<span style=" color: #000;">.</span><a name="bookmark65">&zwnj;</a></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref19" class="a" target="_blank" name="bookmark66">Ayres F, Wambier C. Phenol-croton oil peels. In: da Costa A, ed. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref19" class="s35" target="_blank">Minimally Invasive Aesthetic Procedures for Dermatologists and Plastic Surgeons</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref19" class="a" target="_blank">. Atlanta, GA: Springer Nature; </a>2019<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref20" class="a" target="_blank">Gaspar NG, Gaspar APA, Ai</a>d<span class="s36">^</span><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref20" class="a" target="_blank">e MK. Rhinophyma: practical </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref20" target="_blank">and</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref20" class="a" target="_blank" name="bookmark67">safe treatment with trichloroacetic acid. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref20" class="s35" target="_blank">Surg Cosmet Derma- tol</a>. 2014;6:368-372<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref21" class="a" target="_blank">Yug A, Lane JE, Howard MS, Kent DE. Histologic study of depressed acne scars treated with serial high-concentration (95%) trichloroacetic acid. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref21" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref21" class="a" target="_blank">. </a>2006;32:985-990<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref22" class="a" target="_blank">Lee JB, Chung WG, Kwahck H, Lee KH. Focal treatment of </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref22" target="_blank">acne</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 107%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref22" class="a" target="_blank">scars with trichloroacetic acid: chemical reconstruction of skin scars method. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref22" class="s35" target="_blank">Dermatol Surg</a>. 2002;28:1017-1021<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref23" class="a" target="_blank">Dalpizzol M, Weber MB, Mattiazzi AP, Manzoni AP. Compara- tive study of the use of trichloroacetic acid and phenolic acid in the treatment of atrophic-type acne scars. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref23" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref23" class="a" target="_blank">. </a>2016;42:377-383<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;">Mu<a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref24" class="s38" target="_blank">€</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref24" class="a" target="_blank">hlmann AC, Macedo Fonseca JC, Bai</a><span class="s36">~</span><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref24" class="a" target="_blank">ao Fernando G, Chiara Moc¸o L. Estudo comparativo entre </a>aplicac¸<span class="s36">~</span><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref24" class="a" target="_blank">ao de ATA a 90% e fenol a 88% com a </a>t<a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref24" class="s38" target="_blank">&#39;</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref24" class="a" target="_blank">ecnica de CROSS nas cicatrizes da </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref24" target="_blank">acne.</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref24" class="s35" target="_blank">Med Cutan Ibero Lat Am</a>. 2010;38:189-193<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref25" class="a" target="_blank">Nofal E, Helmy A, Nofal A, Alakad R, Nasr M. Platelet-rich plasma versus CROSS technique with 100% trichloroacetic acid versus combined skin needling and platelet rich plasma in the treatment of atrophic acne scars: a comparative study. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref25" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref25" class="a" target="_blank">. </a>2014;40:864-873<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref26" class="a" target="_blank" name="bookmark68">Rullan PP, Lemon J, Rullan J. The 2-day light phenol chemabrasion for deep wrinkles and acne scars: a presenta- tion of face and neck peels. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref26" class="s35" target="_blank">Am J Cosmet Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref26" class="a" target="_blank">. 2004;21:199- </a>210<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref27" class="a" target="_blank">de Mendonca MC, de Oliveira AR, Araujo JM, Silva M, Gamonal A. Nonsurgical technique for incomplete earlobe cleft repair. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref27" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref27" class="a" target="_blank">. </a>2009;35:446-450<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref28" class="a" target="_blank">Muthuvel K, Sekar S, MS D. Incomplete ear lobe cleft </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref28" target="_blank">repair</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref28" class="a" target="_blank" name="bookmark69">with 100% trichloroacetic acid. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref28" class="s35" target="_blank">Int J Res Dermatol</a>. 2016;2:91<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref29" class="a" target="_blank">Haque MU, Ramesh V. Evaluation of three different strengths of trichloroacetic acid in xanthelasma palpebrarum. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref29" class="s35" target="_blank">J Derma- tolog Treat</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref29" class="a" target="_blank">. </a>2006;17:48-50<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref30" class="a" target="_blank">Cannon PS, Ajit R, Leatherbarrow B. Efficacy of trichloroacetic acid (95%) in the management of xanthelasma palpebrarum. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref30" class="s35" target="_blank">Clin Exp Dermatol</a>. 2010;35:845-848<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref31" class="a" target="_blank">Nahas TR, Marques JC, Nicoletti A, Cunha M, </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref31" target="_blank">Nishiwaki-</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref31" class="a" target="_blank" name="bookmark70">Dantas MC, Filho JV. Treatment of eyelid xanthelasma with 70% trichloroacetic acid. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref31" class="s35" target="_blank">Ophthal Plast Reconstr Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref31" class="a" target="_blank">. 2009;25: </a>280-283<span style=" color: #000;">.</span></p></li><li><p class="s16" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;">Wambier CG. Chemical peels. Presented at the 2018 American Academy of Dermatology Annual Meeting, San Diego, CA, February 16-20, 2018.</p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref33" class="a" target="_blank" name="bookmark71">Safoury OS, Zaki NM, El Nabarawy EA, Farag EA. A study comparing chemical peeling using modified Jessner’s solution and 15% trichloroacetic acid versus 15% trichloroacetic acid in the treatment of melasma. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref33" class="s35" target="_blank">Indian J Dermatol</a>. 2009;54:41-45<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref34" class="a" target="_blank">Abdel-Meguid AM, Taha EA, Ismail SA. Combined </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref34" target="_blank">Jessner</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref34" class="a" target="_blank">solution and trichloroacetic acid versus trichloroacetic acid alone in the treatment of melasma in dark-skinned patients. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref34" class="s35" target="_blank">Dermatol Surg</a>. 2017;43:651-656<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref35" class="a" target="_blank">Brody HJ. Commentary on combined Jessner solution </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref35" target="_blank">and</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref35" class="a" target="_blank" name="bookmark72">trichloroacetic acid versus trichloroacetic acid alone in the treatment of melasma in dark-skinned patients. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref35" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref35" class="a" target="_blank">. </a>2017;43:657<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 107%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref36" class="a" target="_blank">Brody HJ. Variations and comparisons in medium-depth chemical peeling. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref36" class="s35" target="_blank">J Dermatol Surg Oncol</a>. 1989;15:953-963<span style=" color: #000;">.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p class="s18" style="padding-top: 3pt;padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref37" class="a" target="_blank" name="bookmark73">Brody HJ, Hailey CW. Medium-depth chemical peeling of the skin: a variation of superficial chemosurgery. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref37" class="s35" target="_blank">J Dermatol Surg Oncol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref37" class="a" target="_blank">. </a>1986;12:1268-1275<span style=" color: #000;">.</span><a name="bookmark74">&zwnj;</a></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref38" class="a" target="_blank" name="bookmark75">Tse Y, Ostad A, Lee HS, et al. A clinical and histologic evaluation of two medium-depth peels. Glycolic acid versus Jessner’s trichloroacetic acid. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref38" class="s35" target="_blank">Dermatol Surg</a>. 1996;22:781-786<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref39" class="a" target="_blank">Coleman WP 3rd, Futrell JM. The glycolic acid </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref39" target="_blank">trichloroacetic</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref39" class="a" target="_blank" name="bookmark76">acid peel. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref39" class="s35" target="_blank">J Dermatol Surg Oncol</a>. 1994;20:76-80<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 107%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref40" class="a" target="_blank" name="bookmark77">Nelson BR, Fader DJ, Gillard M, Majmudar G, Johnson TM. Pilot histologic and ultrastructural study of the effects of medium- depth chemical facial peels on dermal collagen in patients with actinically damaged skin. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref40" class="s35" target="_blank">J Am Acad Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref40" class="a" target="_blank">. 1995;32: </a>472-478<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref41" class="a" target="_blank" name="bookmark78">Monheit GD. The Jessner’s-trichloroacetic acid peel. An enhanced medium-depth chemical peel. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref41" class="s35" target="_blank">Dermatol Clin</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref41" class="a" target="_blank">. 1995; </a>13:277-283<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 107%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref42" class="a" target="_blank" name="bookmark79">Monheit GD. The Jessner’s 1 TCA peel: a medium-depth chemical peel. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref42" class="s35" target="_blank">J Dermatol Surg Oncol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref42" class="a" target="_blank">. </a>1989;15:945-950<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref43" class="a" target="_blank">Ormerod E, Hughes TM, Stone N. Allergic contact dermatitis caused by resorcinol following a temporary black henna tattoo. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref43" class="s35" target="_blank">Contact Dermatitis</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref43" class="a" target="_blank">. </a>2017;77:187-188<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref44" class="a" target="_blank">Pastor-Nieto MA, Sanchez-Pedreno P, Martinez-Menchon </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref44" target="_blank">T,</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref44" class="a" target="_blank">Melgar-Molero V, Alcantara-Nicolas F, de la Cruz-Murie P. Allergic contact dermatitis caused by phenylethyl resorcinol, a skin-lightening agent contained in a sunscreen. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref44" class="s35" target="_blank">Contact Dermatitis</a>. 2016;75:250-253<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 107%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref45" class="a" target="_blank" name="bookmark80">Langeland T, Braathen LR. Allergic contact dermatitis from resorcinol. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref45" class="s35" target="_blank">Contact Dermatitis</a>. 1987;17:126<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref46" class="a" target="_blank" name="bookmark81">Maloney BP, Millman B, Monheit G, McCollough EG. The etiology of prolonged erythema after chemical peel. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref46" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref46" class="a" target="_blank">. </a>1998;24:337-341<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref47" class="a" target="_blank">Wambier CG, Beltrame FL. Air safety and personal protective equipment for phenol-croton oil peels. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref47" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref47" class="a" target="_blank">. 2018; </a>44:1035-1037<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref48" class="a" target="_blank" name="bookmark82">Wambier CG, Wambier SPF, Pilatti LEP, Grabicoski JA, Wambier LF, Schmidt A. Prolongation of rate-corrected QT interval during phenol-croton oil peels. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref48" class="s35" target="_blank">J Am Acad Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref48" class="a" target="_blank">. </a>2018;78:810-812<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref49" class="a" target="_blank" name="bookmark83">Camacho FM. Medium-depth and deep chemical peels. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref49" class="s35" target="_blank">J Cosmet Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref49" class="a" target="_blank">. </a>2005;4:117-128<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref50" class="a" target="_blank" name="bookmark84">de Mendonca MCC, Segheto NN, Aarestrup FM, Aarestrup BJV. Punctuated 88% phenol peeling for the treatment of facial photoaging: a clinical and histopathological study. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref50" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref50" class="a" target="_blank">. </a>2018;44:241-247<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref51" class="a" target="_blank">Al-Talib H, Al-Khateeb A, Hameed A, Murugaiah C. Efficacy and safety of superficial chemical peeling in treatment of active acne vulgaris. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref51" class="s35" target="_blank">An Bras Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref51" class="a" target="_blank">. </a>2017;92:212-216<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref52" class="a" target="_blank">Dayal S, Amrani A, Sahu P, Jain VK. Jessner’s solution vs. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref52" target="_blank">30%</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref52" class="a" target="_blank">salicylic acid peels: a comparative study of the efficacy and safety in mild-to-moderate acne vulgaris. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref52" class="s35" target="_blank">J Cosmet Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref52" class="a" target="_blank">. </a>2017;16:43-51<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref53" class="a" target="_blank" name="bookmark85">Kligman DE, Draelos ZD. Combination superficial peels with salicylic acid and post-peel retinoids. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref53" class="s35" target="_blank">J Drugs Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref53" class="a" target="_blank">. 2016; </a>15:442-450<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref54" class="a" target="_blank" name="bookmark86">Vemula S, Maymone MBC, Secemsky EA, et al. Assessing the safety of superficial chemical peels in darker skin: a retrospec- tive study. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref54" class="s35" target="_blank">J Am Acad Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref54" class="a" target="_blank">. </a>2018;79:508-513.e2<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref55" class="a" target="_blank">Kessler E, Flanagan K, Chia C, Rogers C, Glaser DA. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref55" target="_blank">Comparison</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref55" class="a" target="_blank" name="bookmark87">of alpha- and beta-hydroxy acid chemical peels in the treatment of mild to moderately severe facial acne vulgaris. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref55" class="s35" target="_blank">Dermatol Surg</a>. 2008;34:45-50<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref56" class="a" target="_blank">Garg VK, Sinha S, Sarkar R. Glycolic acid peels versus </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref56" target="_blank">salicylic-</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref56" class="a" target="_blank">mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref56" class="s35" target="_blank">Der- matol Surg</a>. 2009;35:59-65<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-top: 3pt;padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref57" class="a" target="_blank" name="bookmark88">Jacob CI, Dover JS, Kaminer MS. Acne scarring: a classification system and review of treatment options. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref57" class="s35" target="_blank">J Am Acad Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref57" class="a" target="_blank">. </a>2001;45:109-117<span style=" color: #000;">.</span><a name="bookmark89">&zwnj;</a></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref58" class="a" target="_blank" name="bookmark90">Al-Waiz MM, Al-Sharqi AI. Medium-depth chemical peels in the treatment of acne scars in dark-skinned individuals. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref58" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref58" class="a" target="_blank">. </a>2002;28:383-387<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref59" class="a" target="_blank" name="bookmark91">Brodland DG, Roenigk RK. Trichloroacetic acid chemexfoliation (chemical peel) for extensive premalignant actinic damage of the face and scalp. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref59" class="s35" target="_blank">Mayo Clin Proc</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref59" class="a" target="_blank">. </a>1988;63:887-896<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref60" class="a" target="_blank">Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref60" target="_blank">A</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref60" class="a" target="_blank" name="bookmark92">comparison of the efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref60" class="s35" target="_blank">Arch Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref60" class="a" target="_blank">. 1995;131: </a>176-181<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref61" class="a" target="_blank" name="bookmark93">Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Long-term efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref61" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref61" class="a" target="_blank">. </a>1997;23:191-196<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref62" class="a" target="_blank" name="bookmark94">Robinson JK. Actinic cheilitis. A prospective study comparing four treatment methods. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref62" class="s35" target="_blank">Arch Otolaryngol Head Neck Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref62" class="a" target="_blank">. </a>1989;115:848-852<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref63" class="a" target="_blank" name="bookmark95">Funasaka Y, Abdel-Daim M, Kawana S, Nishigori C. Effect of chemical peeling on the skin in relation to UV irradiation. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref63" class="s35" target="_blank">Exp Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref63" class="a" target="_blank">. 2012;21(suppl </a>1):31-35<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref64" class="a" target="_blank">Abdel-Daim M, Funasaka Y, Kamo T, et al. Effect of chemical peeling on photocarcinogenesis. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref64" class="s35" target="_blank">J Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref64" class="a" target="_blank">.</a> 2010;37:864-872<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref65" class="a" target="_blank" name="bookmark96">Abdel-Daim M, Funasaka Y, Kamo T, et al. Preventive effect of chemical peeling on ultraviolet induced skin tumor formation. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref65" class="s35" target="_blank">J Dermatol Sci</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref65" class="a" target="_blank">. </a>2010;60:21-28<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref66" class="a" target="_blank">Kontochristopoulos G, Kouris A, Platsidaki E, Markantoni </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref66" target="_blank">V,</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 106%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref66" class="a" target="_blank" name="bookmark97">Gerodimou M, Antoniou C. Combination of microneedling and 10% trichloroacetic acid peels in the management of infraorbital dark circles. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref66" class="s35" target="_blank">J Cosmet Laser Ther</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref66" class="a" target="_blank">. 2016;18: </a>289-292<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref67" class="a" target="_blank" name="bookmark98">Vavouli C, Katsambas A, Gregoriou S, et al. Chemical peeling with trichloroacetic acid and lactic acid for infraorbital dark circles. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref67" class="s35" target="_blank">J Cosmet Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref67" class="a" target="_blank">. </a>2013;12:204-209<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref68" class="a" target="_blank">Dayal S, Sahu P, Jain VK, Khetri S. Clinical efficacy and safety </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref68" target="_blank">of</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref68" class="a" target="_blank" name="bookmark99">20% glycolic peel, 15% lactic peel, and topical 20% vitamin C in constitutional type of periorbital melanosis: a comparative study. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref68" class="s35" target="_blank">J Cosmet Dermatol</a>. 2016;15:367-373<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref69" class="a" target="_blank">Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref69" target="_blank">of</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref69" class="a" target="_blank" name="bookmark100">glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref69" class="s35" target="_blank">Dermatol Surg</a>. 2002;28:828-832<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref70" class="a" target="_blank">Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref70" target="_blank">acid</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref70" class="a" target="_blank">chemical peels as a new therapeutic modality in melasma in comparison to Jessner’s solution chemical peels. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref70" class="s35" target="_blank">Dermatol Surg</a>. 2006;32:1429-1436<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref71" class="a" target="_blank">Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid as a new therapeutic peeling agent in melasma. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref71" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref71" class="a" target="_blank">. </a>2005;31:149-154<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref72" class="a" target="_blank" name="bookmark101">Khunger N, Sarkar R, Jain RK. Tretinoin peels versus glycolic acid peels in the treatment of Melasma in dark-skinned patients. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref72" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref72" class="a" target="_blank">. </a>2004;30:756-760<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref73" class="a" target="_blank">Joshi SS, Boone SL, Alam M, et al. Effectiveness, safety, </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref73" target="_blank">and</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref73" class="a" target="_blank">effect on quality of life of topical salicylic acid peels for treatment of postinflammatory hyperpigmentation in dark skin. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref73" class="s35" target="_blank">Dermatol Surg</a>. 2009;35:638-644<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref74" class="a" target="_blank">Tung R, Mahoney AM, Novice K, et al. Treatment of </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref74" target="_blank">lateral</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref74" class="a" target="_blank">canthal rhytides with a medium depth chemical peel with or without pretreatment with onabotulinum toxin type A: a randomized control trial. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref74" class="s35" target="_blank">Int J Womens Dermatol</a>. 2016;2:31-34<span style=" color: #000;">.</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p></li><li><p class="s18" style="padding-top: 3pt;padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref75" class="a" target="_blank" name="bookmark102">Silpa-archa N, Kohli I, Chaowattanapanit S, Lim HW, Hamzavi I. Postinflammatory hyperpigmentation: a comprehensive over- view. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref75" class="s35" target="_blank">J Am Acad Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref75" class="a" target="_blank">. </a>2017;77:591-605<span style=" color: #000;">.</span><a name="bookmark103">&zwnj;</a></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref76" class="a" target="_blank">Hevia O, Nemeth AJ, Taylor JR. Tretinoin accelerates </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref76" target="_blank">healing</a></p><p class="s18" style="padding-left: 19pt;text-indent: 0pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref76" class="a" target="_blank" name="bookmark104">after trichloroacetic acid chemical peel. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref76" class="s35" target="_blank">Arch Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref76" class="a" target="_blank">. 1991; </a>127:678-682<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref77" class="a" target="_blank">Committee for Guidelines of Care for Chemical P. Guidelines for chemical peeling in Japan (3rd edition). </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref77" class="s35" target="_blank">J Dermatol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref77" class="a" target="_blank">. 2012; </a>39:321-325<span style=" color: #000;">.</span></p></li><li><p class="s18" style="padding-top: 3pt;padding-left: 19pt;text-indent: -13pt;line-height: 107%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref78" class="a" target="_blank" name="bookmark105">Khunger N, Force IT. Standard guidelines of care for chemical peels. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref78" class="s35" target="_blank">Indian J Dermatol Venereol Leprol</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref78" class="a" target="_blank">. </a>2008;74(suppl):S5-S12<span style=" color: #000;">.</span><a name="bookmark106">&zwnj;</a></p></li><li><p class="s18" style="padding-left: 19pt;text-indent: -13pt;line-height: 108%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref79" class="a" target="_blank">Garg VK, Sarkar R, Agarwal R. Comparative evaluation of beneficiary effects of priming agents (2% hydroquinone and 0.025% retinoic acid) in the treatment of melasma with glycolic acid peels. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref79" class="s35" target="_blank">Dermatol Surg</a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref79" class="a" target="_blank">. </a>2008;34:1032-1039<span style=" color: #000;">.</span></p></li><li><p style="padding-left: 19pt;text-indent: -13pt;line-height: 9pt;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref80" class="a" target="_blank">Nanda S, Grover C, Reddy BS. Efficacy of hydroquinone </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref80" target="_blank">(2%)</a></p></li></ol><p class="s18" style="padding-left: 19pt;text-indent: 0pt;line-height: 107%;text-align: justify;"><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref80" class="a" target="_blank">versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma. </a><a href="http://refhub.elsevier.com/S0190-9622(18)33049-4/sref80" class="s35" target="_blank">Dermatol Surg</a>. 2004;30:385-388<span style=" color: #000;">.</span></p></body></html>
